SUBMIT YOUR ABSTRACT
DIA invites you to submit a presentation abstract for the 24th DIA Japan Annual Workshop for Clinical Data Management, to be held in Tokyo on February 18-19, 2021.
Presentations can be delivered online or at the venue.
Call for Abstracts: Flyer is here
We are calling for abstracts that show a practical example and/or case-study in the following:
Data quality management from Risk-based Approach (RBA): Examples of data quality check from RBA perspectives or data management challenges in Risk Based Monitoring (RBM)
eSource and patient technology: Experience of eCOA, Smart Trial, mHealth trials, or Electronic Health Record interoperability
DM best practice challenges and training initiatives
Investigator-Led Clinical Trials: Consideration and practices related to DM work, etc.
CDISC Implementation and eData submission: Examples of e-Data submission and data standardization challenge
Real World Data (RWD): Examples of database research, registry data management, and data usage
Submission Deadline: Friday, August 21, 2020 (Japan time)
Notification: by September 25, 2020
All abstracts have to be submitted online at DIAglobal.org/Abstracts
Please read additional information on the Abstracts Details.
Questions? Contact Japan@DIAglobal.org
The COVID-19 Pandemic has impacted the field of clinical data management (CDM) in many ways.
An increased burden on medical institutions, restrictions on movement, and voluntary restraint have meant CDM professionals have been unable to conduct clinical studies, research, and post-marketing surveys as planned. CDM professionals have had to be flexible as the evolving situation has brought about many challenges including restrictions on observations due to patients being unable to visit hospitals, restrictions on monitoring activities (including verifying source documents), and the rise of new methods of communication through remote working. This situation has meant that CDM professionals have been required to adjust quickly to the rapid rise of remote ways of operating. We have also seen the demand for IT infrastructure and data utilization (visualization) increase rapidly.
In July 2019, some 6 months or so before the COVID-19 Pandemic, a notification of a revision to the Good Clinical Practice Guidance (hereinafter referred to as “GCP Guidance”) was issued which made reference to the smooth implementation of clinical trials. The GCP Guidance highlighted the necessity of establishing and executing quality management specifically to deal with computerization in the rapidly growing clinical trial implementation system and to secure the reliability of subject protections and study results. Following this, in April 2020 electronic data submission for applications was fully introduced in Japan. In the future, this will lead to end-to-end data automation and expansion of data utilization. The application of cutting-edge technologies such as regenerative medicine has also boosted collaboration between industry and academia.
With this background, this Workshop will ask, how can clinical data professionals bring about real change and how should we demonstrate leadership in developing new ways of working?
This workshop aims to improve the quality of clinical research and clinical data management activities and will provide meaningful opportunities for networking and information exchange that extend beyond the realms of industry, government, and academia.